Quick Answer
GLP-1 clinics get approved on who bills what, not on compounded versus branded. A clinic billing only consults, while a pharmacy bills the medication, presents the smallest underwriting file. Growth changes that file.
Key Points
- A GLP-1 clinic that bills only the consult, while a licensed pharmacy bills the medication, gives a credit card processing underwriter the smallest file to review.
- In September 2025, a licensed Indiana office got 30 days' notice from its card processor because it billed patients for compounded medications.
- Since July 1, 2026, Medicare's Bridge program has covered semaglutide (Wegovy) and tirzepatide (Zepbound) for eligible Part D patients, with strict limits.
Who bills the consult and who bills the medication shapes a GLP-1 clinic's underwriting file.
Two drugs dominate this market. Dietitian Ana Reisdorf counts semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) as the two main GLP-1 medications. Clinics sell both in compounded and branded form, and owners tend to assume that label decides approval.
So ask a processor up front what it wants to see in your file. Seamless Chex has worked with merchants since Evan and Lily Flanigan founded it in 2012, and the question I'd ask any GLP-1 clinic first is simpler: does it prescribe, dispense, or only refer? Each answer puts a different file in front of the underwriter.
Scrutiny of compounded GLP-1s keeps rising, and a September 2026 analysis described the temperature around them as climbing. Processors have responded by treating GLP-1 underwriting as a full-business review: clinical structure, claims, recurring billing, refunds, disputes, vendors and advertising. Medicare's new GLP-1 coverage hasn't changed that. The drug is one line in the file.
Before you pick a model, work out what each one would cost your clinic to run. I'll admit the trade-off plainly. Handing medication billing to a pharmacy shrinks your file, but it also hands away margin and some control of the patient experience. For most clinics I'd still take the smaller file first, starting with how each operating model reads to an underwriter.
Questions this article answers
Why does the operating model matter more than the drug?
Each operating model changes which refunds and disputes land on your merchant account. A clinic billing only consults carries far less refund and dispute exposure than one that also sells the medication.
Before you apply, answer three questions in plain words:
- Who prescribes: your own clinicians or a partner network.
- Who dispenses: your clinic or a licensed pharmacy.
- Who charges the card for the medication: you or the pharmacy.
The common assumption is that branded drugs sail through and compounded ones fail. That misses the bigger variable. Cleveland Clinic notes GLP-1 medications have "been FDA approved since 2005"; what is new is using them at higher doses for weight loss in patients without diabetes. The coverage backdrop is shifting too. The University of Michigan's Institute for Healthcare Policy and Innovation explained on July 2, 2026 that Medicare was barred for decades from paying for weight-loss drugs, and that its new GLP-1 coverage comes with limits.
An analysis of 5 sources, from clinical podcasts to operator forums, points one way. None of them measured approval rates by operating model, so treat that direction as a guide. Ask each processor which of your charges it would review, and what it needs to see for each one.
In practice, I start every GLP-1 review with the billing map, and our merchant payment processing solutions are built around it. Our co-founder Evan Albert worked in fixed income sales and trading on Wall Street before Seamless Chex, and that habit of reading structure before product still shapes how we look at a file. Which brings us to what each model actually hands the underwriter.
Is it the compounded drug that gets a GLP-1 clinic dropped, or what the clinic bills?
A licensed Indiana office that never made or shipped a single dose still got 30 days' notice from its card processor. The stated reason sounds simple. The details are less so.
The office described its situation on Reddit's payment processing forum in September 2025. A nurse practitioner with a collaborative physician sees most patients in person, and the few telehealth patients are all in Indiana. The office has a physical location, a website and a license, and takes cash pay only. Its mainstream processor said it would close the account "because we offer compounded medications." The poster assumed GLP-1 compounds were the issue, though many patients also take compounded hormone and thyroid medications.
"We do not provide, make or ship medication from our office," the poster wrote. The money moved differently. The office billed patients for their compounded medications, ordered them from a 503A compounding pharmacy that shipped to each patient's home, and paid the pharmacy directly. Every medication charge ran through the clinic's own account, so in payment terms the clinic was selling the drug.
Then came the terms, and the processor left one door open.
Where the processor drew its line
- Allowed: charges taken at point of sale, in the office.
- Refused: payment links sent to patients, "at a minimum," in the poster's words.
- Swept in: compounded hormone and thyroid prescriptions, alongside GLP-1 compounds.
The office valued links because patients could pay without creating a username or downloading an app. Remote collection for a medication the clinic billed was the combination the processor would no longer carry.
One office cannot tell us how every processor decides. Our own underwriting team made the general point in September 2026 about a very different kind of merchant: whatever a business calls its product, the processor is "pricing prepaid credit, a randomized outcome, and delayed physical fulfillment." What gets priced is the shape of the business. A menopause app founder hit the same wall in July 2026, after two boutique merchant-of-record services turned her down. Careful wording and disclaimers made no difference, she wrote, because such services "carry the liability as the seller of record." Her conclusion: "Rewriting your landing page won't fix a category-level policy." Her AI health app shows how little better copy can fix, and says nothing direct about GLP-1 clinics.
Why would compounded medication make that liability heavier? Clinicians point to outside pressure. "Recently, the FDA issued warnings about compounded GLP-1 manufacturers," Kristin Louden said on a Cleveland Clinic podcast, adding that "some of the pharmaceutical companies are going after some of these companies that offer compounded GLP-1s." The FDA says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug," and tells patients with label questions to contact the compounder or "the telehealth platform where you purchased the drug." When a clinic bills for the medication, the clinic is where the patient bought it. Demand persists anyway: in a 2024 thread among medical professionals, one commenter said some patients pay $100 a month for compounded GLP-1s.
Branded drugs now have a route where, for some patients, Medicare covers the drug. Since July 1, 2026, Medicare's Bridge program has covered semaglutide (Wegovy) and tirzepatide (Zepbound) for eligible patients with Part D coverage. Patients cannot apply themselves. A doctor, nurse practitioner or physician assistant must prescribe the drug and attest that the patient meets the program's prior authorization criteria.
| The Indiana office, 2025 | A Medicare Bridge patient, from July 1, 2026 | |
|---|---|---|
| Medication | Compounded GLP-1, hormone and thyroid medications | Branded semaglutide (Wegovy) or tirzepatide (Zepbound) |
| Who pays for the drug | Patient pays the office by card, and the office pays a 503A pharmacy | Covered through the patient's Medicare Part D coverage |
| The clinician's part | Prescribes, bills and orders the drug | Prescribes and attests to eligibility |
| What the processor sees | Medication charges, some collected by remote link | The clinic's own services |
Bridge has real limits. Patients already eligible for a GLP-1 through Medicare for another reason, including Type 2 diabetes, cannot join. Strict BMI and health criteria apply. The program also leaves out what Lauren Oshman, a University of Michigan obesity medicine physician, calls "wraparound services and support."
Across the sources, risk keeps gathering around the medication charge. The FDA warnings and drugmaker pressure target compounded supply, yet in the one case we could document, the processor acted against a clinic that billed the drug and collected remotely, catching hormone and thyroid compounds along the way. When the pharmacy or a drug plan charges for the medication, the underwriter is left mostly with the clinic's own services to judge. With one firsthand case and no measured approval rates, treat this as a pattern to test with any processor.
Before you apply
- List every charge that runs through your merchant account: the consult, any medication, and any compounded hormone or thyroid prescriptions alongside GLP-1s.
- If you bill patients for medication and pay the pharmacy yourself, ask your 503A pharmacy whether it can bill patients directly, and ask a processor how that change would affect its review.
- Ask any processor, us included, which channels it allows for each type of charge: an in-office terminal, remote payment links, or both.
- Have your pharmacy agreements and business documents ready before you apply. One commenter in the Indiana thread said some providers require them upfront.
- For patients with Medicare Part D, check Bridge eligibility, since an eligible patient's branded drug is covered through Medicare.
How we checked this
We used three Reddit threads (one clinic's own account, a health app founder's account, and a discussion among medical professionals), a Cleveland Clinic podcast, FDA guidance, a University of Michigan explainer on Medicare's Bridge program, and comments from our own underwriting team. The underwriting quote is ours, and it describes a different merchant category. The Indiana case is one anonymous, unverified account, and we know the processor's reasoning only as the poster relayed it. Most replies in that thread came from vendors looking for business. The founder's case concerns an AI app and merchant-of-record services, not a clinic. We sell card processing to high-risk businesses that other processors turn away, so we gain if clinics come to doubt mainstream processors. Still unknown: how many processors draw the same channel line, and whether clinics whose pharmacy bills the drug are approved more often. None of our sources measured approval rates.
- r/PaymentProcessing, telehealth office seeking a new processor, September 2025.
- r/Femalefounders, menopause app founder on two processor rejections, July 2026.
- Kristin Louden, Cleveland Clinic, Butts and Guts podcast on GLP-1 medications, date not stated.
- U.S. Food and Drug Administration, concerns with unapproved GLP-1 drugs, retrieved October 19, 2026.
- r/medicine, discussion of weight loss clinics and compounding, May 2024.
- University of Michigan Institute for Healthcare Policy and Innovation, explainer on Medicare's Bridge GLP-1 coverage, July 2, 2026.
- Seamless Chex underwriting team, comments on how processors price merchant business models, September 2026.
What does each GLP-1 model put in the underwriting file?
Each model hands over a different set of risks. Dispensing clinics carry the medication and its disputes, prescribe-only clinics carry the consult, and referral clinics carry their marketing.
| What the underwriter reviews | Prescribe and dispense | Prescribe only (pharmacy bills the drug) | Refer only |
|---|---|---|---|
| What your card terminal charges | Consult plus medication | Consult or membership fee | Program or coaching fee |
| Product and source disclosure | Every molecule, dose and supplier | Your pharmacy partner and its licensing | Your prescribing partner |
| Refund and dispute exposure | Highest: shipping, side effects, dose changes | Lower: service disputes only | Moderate: claims made in advertising |
| Recurring billing shape | Monthly refills with rising doses | Flat monthly consult | Fixed program term |
The prescribe-only file is the smallest. The pharmacy carries the drug charge. You carry a predictable service fee.
Dispensing clinics face a growing list, and I'd plan for it rather than hope it stays short. Tirzepatide added a second hormone target alongside semaglutide, and clinicians expect more peptide-based drugs to follow. Every new molecule on your menu is another line an underwriter will ask you to explain.
Insurance does not erase this. The University of Michigan explainer stresses that Medicare's new coverage has limits, so most GLP-1 telehealth revenue still runs through cash-pay credit card processing. Larger dispensing operations often need high-volume credit card processing with reserves sized to refill cycles, and that sizing starts with the application itself.
How should a GLP-1 clinic prepare its credit card processing application?
Show the underwriter exactly who bills what, disclose every product and partner, and apply once the business is established and processing steady monthly volume.
Four things belong in the file before you submit:
- A product list: every molecule, dose range and supplier you touch.
- A billing map: which charges you run and which your pharmacy or prescribing partner runs.
- Written cancellation and refund terms for every recurring plan.
- Your growth plans: new locations, new owners or new products in the next year.
Clinical safety helps, but it only goes so far. Cleveland Clinic points to "extensive long-term safety data from millions of patients" on GLP-1s for diabetes. Put your pharmacy partner's licensing in the file alongside that safety record. A clean safety record for the drug class won't explain a confusing descriptor or a vague refund page.
Growth is the step clinics skip most often. In 2025, a bootstrapped single-location clinic owner described reaching "~$200k in revenue" and asked how to expand. A second location, a new partner or an added molecule changes your file. I would raise it with your processor before launch, not after a reserve lands.
Eligibility matters too. SeamlessChex works with established businesses processing a minimum of $25,000 per month, so this is a step for operating clinics, not launches. If your menu already reaches beyond GLP-1s, our deep dive on peptide payment processing covers how product breadth shows up in underwriting, and the rest of this piece looks at whether Medicare changes any of it.
What should GLP-1 clinics do next?
Settle who bills the medication before you apply. Write that answer into a one-page billing map and send it with every processor application you submit.
That file will only get harder to keep small. On the Sound Bites podcast, dietitian Ana Reisdorf noted that "there are more coming that target all sorts of other peptides." Each one is a new disclosure for a dispensing clinic. My advice is simple. Map your billing now, while the menu is short, and apply for a credit card merchant account that fits the model you actually run, with confidence that the file matches the business.
Frequently Asked Questions
What else do clinic owners ask about GLP-1 telehealth payment processing?
What is GLP-1 telehealth payment processing?
GLP-1 telehealth payment processing is credit card processing for clinics that prescribe, dispense or refer patients for GLP-1 weight-loss medication online. Processors usually treat it as high-risk. The underwriting depends on which of those charges your clinic runs.
Does compounded or branded medication decide approval?
Not on its own. Who bills the medication matters more. A clinic billing only consults, with the pharmacy billing the drug, gives the underwriter the least to review.
Does billing insurance make a GLP-1 clinic easier to approve?
Not automatically. In a 2024 physician discussion, an obesity-clinic clinician said some insurers required a 3 to 6 month comprehensive weight management program before covering anti-obesity medications. Those programs add services to your file. They don't remove the card billing.
How fast can a GLP-1 clinic get set up?
SeamlessChex offers same-day onboarding with no contracts, once underwriting approves the file. Apply through the SeamlessChex contact page.
Can a GLP-1 clinic take payments online and in person?
Yes. SeamlessChex lets businesses accept credit card and ACH payments online or in person, which suits clinics that see patients by video and on site.
Written by
Lily Flanigan
Operations Manager, SeamlessChex
Lily Flanigan is Operations Manager at SeamlessChex, a credit card processing and fintech payments platform recognized on the Inc. 5000, where she focuses on operations and process optimization.
Connect on LinkedInSeamlessChex works with established businesses processing a minimum of $25,000 per month.